Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1409
- Registration Number
- NCT02756832
- Locations
- 🇷🇺
City policlinic #3, Tomsk, Russian Federation
🇷🇺Chita State Medical Academy, Chita, Russian Federation
🇷🇺City polyclinic #166, Moscow, Russian Federation
International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1945
- Registration Number
- NCT02756819
- Locations
- 🇰🇿
Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan
🇰🇿Kazakh Medical University of Continuing Education, Almaty, Kazakhstan
🇷🇺Medical center Lotos, Chelyabinsk, Russian Federation
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PlaceboBiological: Tetravalent Dengue Vaccine (TDV)
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20099
- Registration Number
- NCT02747927
- Locations
- 🇨🇴
Centro de Atencion e Investigacion Medica S.A - CAIMED - Aguazul - PPDS-PV, Aguazul, Casanare, Colombia
🇨🇴Centro de Atencion e Investigacion Medica S.A. - CAIMED - Acacias - PPDS-PV, Acacias, Meta, Colombia
🇳🇮Universidad Nacional Autonoma de Nicaragua, Leon, Nicaragua
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
- Conditions
- Gastroesophageal Reflux
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 256
- Registration Number
- NCT02743949
- Locations
- 🇪🇪
OU Innomedica, Tallinn, Estonia
🇵🇱NZOZ Inter-Med, Czestochowa, Poland
🇬🇧Royal Stoke University Hospital, Stoke on Trent, Staffordshire, United Kingdom
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 331
- Registration Number
- NCT02743806
- Locations
- 🇦🇺
The Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺Western Hospital, Footscray, Victoria, Australia
🇦🇺Box Hill Hospital, Box Hill, Australia
Lubiprostone for Chronic Idiopathic Constipation Treatment
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 211
- Registration Number
- NCT02729909
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT02728895
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸OSU - James Comprehensive Cancer Center, Columbus, Ohio, United States
TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: TAK-020 SDTDrug: TAK-020 Captisol Oral SolutionDrug: TAK-020 CCTDrug: TAK-020 IRTDrug: TAK-020 Solid Formulation
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 25
- Registration Number
- NCT02723201
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 334
- Registration Number
- NCT02716116
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Lumi Research, Houston, Texas, United States
A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Takeda
- Registration Number
- NCT02713061